Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 6.4% Higher – Should You Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s share price traded up 6.4% during trading on Friday . The stock traded as high as $8.07 and last traded at $8.01. 6,172,864 shares changed hands during trading, a decline of 61% from the average session volume of 15,742,962 shares. The stock had previously closed at $7.53.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $8.75.

Recursion Pharmaceuticals Stock Performance

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The company’s 50-day moving average price is $6.90 and its two-hundred day moving average price is $6.94. The company has a market cap of $2.86 billion, a P/E ratio of -4.79 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the previous year, the business posted ($0.43) earnings per share. The company’s quarterly revenue was up 147.6% on a year-over-year basis. As a group, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Transactions at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $6.72, for a total transaction of $76,923.84. Following the sale, the director now owns 7,077,560 shares in the company, valued at approximately $47,561,203.20. The trade was a 0.16 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the sale, the chief financial officer now directly owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 37,894 shares of company stock valued at $279,279 over the last three months. Company insiders own 15.75% of the company’s stock.

Institutional Trading of Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in RXRX. Allspring Global Investments Holdings LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter worth $25,000. Decker Retirement Planning Inc. purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth about $26,000. GAMMA Investing LLC boosted its position in Recursion Pharmaceuticals by 1,979.2% during the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after acquiring an additional 4,948 shares during the period. Farther Finance Advisors LLC grew its stake in Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Recursion Pharmaceuticals by 79.9% in the third quarter. KBC Group NV now owns 7,602 shares of the company’s stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.